Fenbendazole Cancer

Fenbendazole (FEN) is a widely used antihelminthic drug that has been shown to have cytotoxic and cytostatic properties in cancer cells. This article presents a case of a patient with advanced nonsmall cell lung cancer (NSCLC) who obtained information on the use of fenbendazole to treat her tumor from social media, and then self-administered it. The patient’s tumor remained stable over time, but she died of other complications, including pneumonia. This case highlights the risks of sharing medical information on online forums and the need for physicians to educate patients about obtaining reliable and proven cancer treatment information.

The effect of varying concentrations and incubation periods of fenbendazole on the survival of EMT6 tumor cells in vitro was determined using a colony formation assay. Intensive treatments with fenbendazole significantly reduced the number of colonies formed. These results indicate that fenbendazole has both cytotoxic and cytostatic effects on EMT6 cells in vitro.

In addition, experiments examining the effect of fenbendazole on radiation sensitivity in EMT6 mammary carcinoma tumor-bearing mice were conducted. Cultures were sealed in stainless steel pressure vessels with needles for the influx and efflux of gases to produce hypoxia and were treated with either vehicle or fenbendazole. After the indicated times, cultures were irradiated. The surviving fractions were determined, and the data were normalized to reflect the cell numbers present at the end of the experiment. The dose-response curves of the irradiation and fenbendazole treatments were superimposed, showing that the 2 drugs produced additive toxicity. fenbendazole cancer